There is also a significant difference in the frequency of infections in individuals who use etanercept compared to those taking mAb-based treatments (Wallis et al., 2004).While anti-TNF-α mAbs exclusively bind to TNF-α, etanercept’s TNF-R domain also binds to lymphotoxin-α (otherwise known as TNF-β), reducing the etanercept available that can bind TNF-α (Cope et al., 1992; Schneider et al., 2004; Murdaca et al., 2012). Here, TNFRSF1A is linked to infection.